Response of first attack of inflammatory bowel disease requiring hospital admission to steroid therapy;Respuesta al tratamiento esteroideo del primer brote de enfermedad inflamatoria intestinal que requiere ingreso hospitalario

Revista Espanola de Enfermedades Digestivas

Volumn 96, Issue 8, 2004, Pages 539-547

  Abu Suboh Abadia M ^a   Casellas, Francesc ^a   Vilaseca, J ^a   Malagelada, J R ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Corticosteroids; Crohn's disease; Inflammatory bowel disease; Prognostic factors; Severe relapse; Treatment; Ulcerative colitis

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; ENOXAPARIN; MESALAZINE; METHYLPREDNISOLONE;

ADULT; ARTICLE; CLINICAL PROTOCOL; CROHN DISEASE; DIET THERAPY; DISEASE EXACERBATION; DISEASE SEVERITY; FEMALE; FLUID THERAPY; HOSPITAL ADMISSION; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PARENTERAL NUTRITION; PREDICTION; REMISSION; RETROSPECTIVE STUDY; SYSTEMIC THERAPY; ULCERATIVE COLITIS;

EID: 5644304648     PISSN: 11300108     EISSN: None     Source Type: Journal    
DOI: 10.4321/S1130-01082004000800003     Document Type: Article

References (25)

1. Fraser AG, Orchard TR, Jewell DP. The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review. Gut 2002; 50: 485-9.
2. Shepherd HA, Barr GD, Jewell DP. Use of an intravenous steroid regimen in the treatment of acute Crohn's disease. J Clin Gastroenterol 1986; 8: 154-9.
3. Oshitani N, Kitano A, Matsumoto T, Kobayashi K. Corticosteroids for the management of ulcerative colitis. J Gastroenterol 1995; 30 (Supl.) 8: 118-20.
4. Summers RW, Switz DM, Sessions JT, Becktel JM, Best WR, Kern F, et al. National cooperative Crohn's disease study; results of drug treatment. Gastroenterology 1979; 77: 847-69.
5. Malchow H, Ewe K, Brandes JW, Goebell H, Ehms H, Summer H, et al. European cooperative Crohn's disease study (ECCDS): results of drug treatment. Gastroenterology 1984; 86: 249-66.
6. Cohen RD, Stein R, Hanauer SB. Intravenous cyclosporin in ulcerative colitis: a five year experience. Am J Gastroenterol 2000; 95: 830.
7. Hyde GM, Thillainayagam AV, Jewell DP. Intravenous cyclosporin as rescue therapy in severe ulcerative colitis: time for a reappraisal?. Eur J Gastroenterol Hepatol 1998; 10: 411-3.
8. Santos JV, Baudet JA, Casellas F, Guarner L, Vilaseca J, Malagelada JR. Efficacy of intravenous cyclosporine for steroid refractory attacks of ulcerative colitis. J Clin Gastroenterol 1995; 20: 285-9.
9. Paoluzi OA, Pica R, Marcheggiano A, Crispino P, Iacopini F, Iannon C, et al. Azathioprine or methotrexate in the treatment of patients with steroid-dependent or steroid-resistant ulcerative colitis: results of an open-label study on efficacy and tolerability in inducing and maintaining remission. Aliment Pharmacol Ther 2002; 16: 1571-80.
10. Alfandhli AA, McDonald JW, Feagan BG. Methotrexate for induction of remission in refractory Crohn disease. Cochrane Database Syst Rev 2003; (1): CD003459.
11. Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, van Hogerzand RA, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999; 340: 1398-405.
12. Hodgson HJF, Bhatti M. Assessment of disease activity in ulcerative colitis and Crohn's disease activity. Inflamm Bowel Dis 1995; 1: 117-43.
13. Harvey RF, Bradshaw JM. A simple index of Crohn's disease activity. Lancet 1980; 1: 514.
14. Rachmilewitz D. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: A randomized trial. BMJ 1989; 298: 82-6.
15. Munkholm P, Langholz E, Davidsen E, Binder V. Frequency of glucocorticoid resistance and dependency in Crohn's disease. Gut 1994; 35: 360-2.
16. Faubion WA, Edward V, Loftus JF, Harmsen WS, Zinsmeister AR, Sandborn J. The natural history of costicosteroid therapy for inflamatory bowel disease: a population-based study. Gastroenterology 2001: 121: 255-60.
17. Kornbluth A, Marion J-F, Salomon P, Janowitz HD. How effective is current medical therapy for severe ulcerative and Crohn's colitis? J Clin Gastroentol 1995; 20: 280-4.
18. Medina C, Vergara M, Casellas F, Lara F, Naval J, Malagelada JR. Influencia del hábito tabáquico en la cirugía de la. enfermedad inflamatoria intestinal. Rev Esp Enferm Dig 1998; 90: 771-4.
19. Gelbmann CM. Position of treatment refractoriness in ulcerative colitis and Crohn's disease-Do we have reliable markers? Inflam Bowel Diseases 2000; 6: 123-31.
20. Malchow H, Steinhardt HJ, Lorenz-Meyer H. Feasability and effectiveness of a defined-formula diet regimen in treating active Crohn's disease. European Cooperative Crohn's Disease Study III. Scand J Gastroenterol 1990; 25: 235-44.
21. Lindgren SC, Flood LM, Kilander AF, Löfberg R, Persson TB, Sjödahl RI. Early predictors of glucocorticoids treatment failure in severe and moderately severe attacks of ulcerative colitis. Eur J Gastroenterol Hepatol 1998; 10: 831-5.
22. Travis SPL, Farrant JM, Rickets C, Nolan DJ, Mortensen NM, Kettlewell MGW, et al. Predicting outcome in severe ulcerative colitis. Gut 1996; 38: 905-10.
23. Bitton A, Peppercorn MA, Antonioli DA, Niles JL, Shah S, Bousvaros A, et al. Clinical, biological and histologic parameters as predictors of relapse in ulcerative colitis. Gastroenterology 2001; 120: 13-20.
24. Loftus EV, Schoenfeld P, Sandborn WJ. The epidemiology an natural history of Crohn's disease in population-based patient cohorts from North America: a systematic review. Aliment Pharmacol Ther 2002; 16: 51-60.
25. Franchimont DP, Louis E, Croes F, Belaiche J. Clinical pattern of corticosteroid dependent Crohn's disease. Eur J Gastroenterol Hepatol 1998; 10: 821-5.